Search Results - "Wu, Ruby"

Light‐activated photosealing with human amniotic membrane strengthens bowel anastomosis in a hypotensive, trauma‐relevant swine model by Scott, Benjamin B., Wang, Ying, Wu, Ruby C., Randolph, Mark A., Redmond, Robert W.

“…Background Gastrointestinal anastomotic leakage is a dreaded complication despite advancements in surgical technique. Photochemical tissue bonding (PTB) is a…”
Get full text

Light-Activated Vascular Anastomosis by Scott, Benjamin B., Randolph, Mark A., Guastaldi, Fernando P. S., Wu, Ruby C., Redmond, Robert W.

“…Background. There have been few advances in technique since vascular anastomosis was performed with silk suture on a curved needle in 1902. This technique…”
Get full text

A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events by Lee, Shing M, Miao, Jieling, Wu, Ruby, Unger, Joseph M, Cheung, Ken, Hershman, Dawn L

“…Cancer treatments are associated with a multitude of adverse events (AEs). While both nurses and physicians are involved in patient care delivery and AE…”
Get full text

A Photosealed Cap Prevents Disorganized Axonal Regeneration and Neuroma following Nerve Transection in Rats by Scott, Benjamin B., Wu, Ruby C., Nietlispach, Viviane, Randolph, Mark A., Redmond, Robert W.

“…Neuroma is a common sequela of traumatic peripheral nerve injury that can result in pain and decreased quality of life for patients. Neuromas result from…”
Get full text

IMPLEMENTATION OF A STANDARDIZED ANTINEOPLASTIC TELEHEALTH EDUCATION WORKFLOW - QUALITY IMPROVEMENT INITIATIVE by Brown, Jessica, Armentano, Francine, Brafman, Lois, Fuentes, Deborah, Wu, Ruby, Accordino, Melissa

“…ASCO-ONS 2016 guidelines specify the necessity of patient antineoplastic education with documentation prior to antineoplastic administration. Advanced Practice…”
Get full text

Abstract P1-19-27: Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC) by Kalinsky, Kevin, Chiuzan, Cody, Onishi, Maika, Trivedi, Meghna S, Accordino, Melissa, Zeleke, Tizita, Pan, Qingfei, Kelly, Sean, Honan, Erin, Wu, Ruby, Fenn, Kathleen, Crew, Katherin D, Hershman, Dawn L, Maurer, Matthew, Yu, Jiyang, Silva, Jose

“…Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function…”
Get full text

Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat by Pan, Qingfei, Zeleke, Tizita, Chiuzan, Cody, Onishi, Maika, Alvarez, Mariano, Honan, Erin, Yang, Min, Chia, Pei Ling, Mukhopadhyay, Partha, Kelly, Sean, Wu, Ruby, Fenn, Kathleen, Trivedi, Meghna, Accordino, Melissa, Crew, Katherine, Hershman, Dawn, Maurer, Matthew, Jones, Simon, Califano, Andrea, Kalinsky, Kevin, Yu, Jiyang, Silva, Jose

“…Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of…”
Get full text

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer by Zeleke, Tizita Z, Pan, Qingfei, Chiuzan, Codruta, Onishi, Maika, Li, Yuxin, Tan, Haiyan, Alvarez, Mariano J, Honan, Erin, Yang, Min, Chia, Pei Ling, Mukhopadhyay, Partha, Kelly, Sean, Wu, Ruby, Fenn, Kathleen, Trivedi, Meghna S, Accordino, Melissa, Crew, Katherine D, Hershman, Dawn L, Maurer, Matthew, Jones, Simon, High, Anthony, Peng, Junmin, Califano, Andrea, Kalinsky, Kevin, Yu, Jiyang, Silva, Jose

“…Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical…”
Get full text

Network-based assessment of HDAC6 activity predicts pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer by Zeleke, Tizita Z., Pan, Qingfei, Chiuzan, Codruta, Onishi, Maika, Li, Yuxin, Tan, Haiyan, Alvarez, Mariano J., Honan, Erin, Yang, Min, Chia, Pei Ling, Mukhopadhyay, Partha, Kelly, Sean, Wu, Ruby, Fenn, Kathleen, Trivedi, Meghna S., Accordino, Melissa, Crew, Katherine D, Hershman, Dawn L, Maurer, Matthew, Jones, Simon, High, Anthony, Peng, Junmin, Califano, Andrea, Kalinsky, Kevin, Yu, Jiyang, Silva, Jose

“…Inhibiting individual histone deacetylases (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through pre-clinical…”
Get full text